FDA Approves New Eye Drop for Farsightedness and Thyroid Eye Disease Treatment

The U.S. Food and Drug Administration (FDA) has approved a novel eye drop designed to correct presbyopia, offering a non-surgical option for age-related farsightedness. Additionally, the FDA granted approval for a new treatment targeting thyroid eye disease, addressing a previously unmet medical need. These regulatory actions introduce new therapeutic avenues, potentially improving quality of life for many patients with common and debilitating eye conditions.